Search

Compugen Ltd

Uždarymo kaina

2.45 1.66

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.4

Max

2.46

Pagrindiniai rodikliai

By Trading Economics

Pajamos

663K

-7M

Pardavimai

426K

2.6M

P/E

Sektoriaus vid.

6.526

56.432

Pelnas, tenkantis vienai akcijai

-0.07

Pelno marža

-269.254

Darbuotojai

75

EBITDA

665K

-7M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+107.47% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

9.8M

235M

Ankstesnė atidarymo kaina

0.79

Ankstesnė uždarymo kaina

2.45

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-17 23:56; UTC

Targa Resources Corp is trading modestly higher in after-market hours, recovering from an early decline and reaching a high near the session's end.

2026-09-17 23:56; UTC

Correlated Moves

Synaptics Inc declined during after-market hours, moving lower alongside the Nasdaq 100 Index amid positive economic data, including a drop in jobless claims.

2026-09-17 23:56; UTC

TransUnion is trading modestly higher in after-market hours, despite earlier gains settling and the price remaining below its 20-day moving average.

2026-09-17 23:56; UTC

Event
News

Rexford Industrial Realty completed a $1.2 billion sale of a 22-property portfolio to EQT Real Estate, with shares slightly declining in after-market trading.

2026-09-17 23:56; UTC

Correlated Moves

Saia Inc's shares traded roughly flat during after-market hours, remaining below the 20-day moving average and near the lower end of its one-month range.

2026-09-17 23:56; UTC

Fidelity National Information Services Inc is trading modestly higher in after-market hours following four consecutive sessions of losses, amid positive economic indicators.

2026-09-17 23:52; UTC

Pinterest Inc is trading higher in after-market hours, continuing a trend of higher daily closes since Thursday's close, despite recent divergence from upward momentum.

2026-09-17 23:51; UTC

Organon & Co. is experiencing a modest decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month trading range.

2026-09-17 23:51; UTC

Hawkins Inc is advancing in after-market trading, reaching its highest cumulative return of the day amid a one-month trading range.

2026-09-17 23:51; UTC

Turning Point Brands Inc has advanced in after-market trading, recovering sharply from a low immediately following Thursday's close, contributing to an overall higher position.

2026-09-17 23:51; UTC

TransDigm Group Inc is seeing modest gains in after-market trading, recovering from earlier lows but remains below its 20-day moving average.

2026-09-17 23:51; UTC

American Electric Power Company Inc is trading modestly lower in after-market hours, continuing a decline from Thursday's close and remaining below its 20-day moving average.

2026-09-17 23:51; UTC

Alliant Energy Corp is trading modestly higher in after-market hours, showing stability with slight upward movement and fluctuations within a narrow range.

2026-09-17 23:51; UTC

Correlated Moves

BHP Group Ltd is advancing in after-market trading, reflecting a notable upward movement since Thursday's close, despite remaining below its 20-day moving average.

2026-09-17 23:51; UTC

CRISPR Therapeutics AG declined modestly during after-market hours on Thursday, breaking a recent trend of higher daily closes.

2026-09-17 23:51; UTC

Chicago Fed National Activity Index Release on September 21, 2026: Market Awaits Insights Amid Cautious Optimism and Inflation Concerns.

2026-09-17 23:51; UTC

Mortgage Rates Hit 6.97%, Highest Since May 2025, as Market Sentiment Wanes Ahead of Upcoming MBA Release

2026-09-17 23:51; UTC

Japan's Core Inflation Rate for August at 1.7% Falls Short of Expectations, Raising Concerns Over Economic Stability and Monetary Policy Effectiveness

2026-09-17 23:51; UTC

Japan's August Inflation Rate at 1.9% Falls Short of Expectations, Raising Concerns for Monetary Policy Adjustments Amidst Weak Demand

2026-09-17 23:51; UTC

Correlated Moves

Las Vegas Sands Corp is trading modestly higher in after-market hours, following a pullback earlier in the session, aligning with Wynn Resorts Ltd's gains.

2026-09-17 23:51; UTC

Regeneron Pharmaceuticals Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average after a volatile session.

2026-09-17 23:51; UTC

FedEx Corp is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month trading range.

2026-09-17 23:51; UTC

ICU Medical Inc declined in after-market trading, reaching its lowest point shortly after the market closed and remaining below its 20-day moving average.

2026-09-17 23:51; UTC

In after-market trading, Dave and Buster's Entertainment, Inc. is advancing, reflecting a notable increase since Thursday's close, despite being below its 20-day moving average.

2026-09-17 23:51; UTC

SLB NV is trading modestly higher in after-market hours, following fluctuations that led to a cumulative return of 0.89% shortly after the market closed.

2026-09-17 23:51; UTC

Correlated Moves

Cardinal Health Inc is trading modestly higher in after-market hours, following a slight uptick in Cencora Inc, which is recovering from recent declines.

2026-09-17 23:51; UTC

Bath & Body Works Inc. is declining in after-market trading, currently near its lowest point of the day and below its 20-day moving average.

2026-09-17 23:46; UTC

Ecolab Inc is trading modestly higher in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

2026-09-17 23:46; UTC

Daqo New Energy Corp is trading higher in after-market hours, closing at its highest point despite challenges, as U.S. jobless claims fell to 196k.

2026-09-17 23:46; UTC

N-Able Inc gained in after-market trading, advancing since Thursday's close and stabilizing above its 20-day moving average near the upper end of its one-month range.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

107.47% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  107.47%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat